IJIAC
Vol. 06, No 03, pp. 63, 84.
Published by TensorGate
OPEN ACCESS
International Journal of Intelligent
Automation and Computing

Adaptive and Maladaptive Neural Plasticity in Pain Processing: Insights into Mechanisms of Neural Injury and Strategies for Targeted Interventions

Musliudeen Toheeb Akanbi

11, August, 2024

Recieved: 02, Jan, 2024. | Revised: 26 July 2024. | Published: 10 August 2024

Abstract

Pain processing is inherently dynamic, involving changes in the nervous system that can be either adaptive or maladaptive. Adaptive neural plasticity is essential for recovery from injury, facilitating adjustments in sensory pathways and promoting healing. In contrast, maladaptive plasticity contributes to the persistence of pain by altering synaptic function, neuronal excitability, and network connectivity, leading to chronic pain conditions. Following nerve injury, plastic changes occur at multiple levels of the nervous system, including the peripheral nervous system (PNS), spinal cord, and brain, resulting in heightened pain sensitivity and abnormal pain responses. Key molecular mechanisms underlying these changes include alterations in ion channels, receptor function, and intracellular signaling pathways such as mitogen-activated protein kinases (MAPKs) and neurotrophic factors like BDNF (brain-derived neurotrophic factor). Maladaptive plasticity leads to phenomena such as central sensitization, where spinal neurons exhibit increased responsiveness to sensory inputs, and altered cortical representations of pain. Understanding the balance between adaptive and maladaptive plasticity provides insights into potential therapeutic strategies aimed at promoting beneficial neural adaptations while suppressing pathological changes. This review explores the mechanisms of neural plasticity in pain processing, highlighting molecular and cellular processes involved in neural injury and repair. We discuss targeted interventions, including pharmacological agents, neuromodulation, and regenerative approaches, that aim to modulate neural plasticity and improve outcomes for individuals suffering from chronic pain.

Keywords: *adaptive plasticity, BDNF, central sensitization, ion channels, maladaptive plasticity, MAPK pathways, neural plasticity*

1 Introduction

Pain is a complex and multifaceted experience that involves dynamic changes in neural circuits in response to injury or disease. These changes, broadly referred to as neural plasticity, enable the nervous system to adapt to new stimuli and recover from damage. Neural plasticity encompasses various forms of functional and structural modifications in the nervous system, including alterations in synaptic strength, changes in neuronal excitability, and the reorganization of neural networks. This capacity for change allows the nervous system to be highly adaptable, supporting processes such as learning, memory, and recovery following injuries. However, when these changes become excessive or persist beyond the healing phase, they can lead to maladaptive plasticity, characterized by the chronic amplification of pain signals. This transition from acute to chronic pain is often associated with alterations in both peripheral and central neural pathways, resulting in the abnormal processing of nociceptive information, which can prolong and intensify the pain experience.

The process of adaptive plasticity is essential for the resolution of acute pain, playing a critical role in mechanisms such as axonal regeneration, synaptic strengthening, and the restoration of disrupted sensory pathways. During the acute phase of pain, adaptive plasticity involves adjustments that enable the nervous system to cope with and respond to injury, ensuring that appropriate pain signals are transmitted and eventually resolved as the body heals. This type of plasticity allows the nervous system to adjust to changes in sensory input, maintain homeostasis, and support recovery by reinforcing circuits that aid in protection and healing. For instance, after peripheral nerve injury, axonal sprouting and synaptic repair mechanisms help re-establish functional connections between neurons, thereby facilitating the restoration of normal sensory function.

In contrast, maladaptive plasticity contributes significantly to chronic pain conditions by disrupting normal pain processing mechanisms and leading to persistent alterations in the function of sensory neurons, dorsal horn neurons in the spinal cord, and brain regions involved in pain perception. Maladaptive changes can manifest as increased excitability of nociceptors—sensory neurons that detect noxious stimuli—resulting in the heightened sensitivity of affected tissues to pain, a phenomenon known as hyperalgesia. Additionally, enhanced synaptic transmission within spinal and supraspinal pain pathways can lead to a phenomenon called central sensitization, wherein pain signals become amplified and prolonged. This sensitization is often accompanied by structural changes in the neural circuits that process pain, such as the sprouting of sensory fibers into inappropriate regions or the reorganization of cortical areas that mediate pain perception.

Understanding the mechanisms underlying both adaptive and maladaptive plasticity is crucial for developing targeted interventions that can modulate these processes and provide effective pain relief. A deeper understanding of these processes enables researchers and clinicians to identify molecular targets that can shift the balance from maladaptive to adaptive responses, thereby alleviating chronic pain without compromising the necessary protective functions of acute pain. This review explores the molecular and cellular mechanisms of neural plasticity in pain processing, with a particular focus on the role of ion channels, neurotransmitters, and intracellular signaling pathways that mediate plastic changes. Ion channels such as voltage-gated sodium channels (Nav), transient receptor potential (TRP) channels, and potassium channels are known to modulate the excitability of sensory neurons and play a significant role in the development of pain hypersensitivity. Similarly, neurotransmitters like glutamate, gamma-aminobutyric acid (GABA), and endogenous opioids are crucial in shaping synaptic transmission within pain pathways.

Moreover, the intracellular signaling cascades that these molecules activate, such as protein kinase pathways (e.g., protein kinase C, mitogen-activated protein kinases), contribute to long-term changes in synaptic strength and neuronal excitability, underpinning both adaptive and maladaptive forms of plasticity. The intricate interplay between these molecular mediators ultimately determines whether the neural adaptations following injury result in resolution of pain or its chronic persistence.

In addition to exploring these fundamental mechanisms, this review discusses therapeutic strategies that aim to enhance adaptive plasticity and suppress maladaptive changes, including pharmacological agents, neuromodulation techniques, and regenerative therapies. Pharmacological interventions often target specific ion channels or neurotransmitter systems to modulate pain transmission, such as using sodium channel blockers, NMDA receptor antagonists, or GABA agonists to reduce neuronal excitability and central sensitization. Neuromodulation techniques, including spinal cord stimulation, transcranial magnetic stimulation, and peripheral nerve stimulation, offer non-pharmacological approaches to influence pain pathways directly, often by altering the activity of neural circuits involved in pain processing. Regenerative therapies, such as stem cell transplantation and gene therapy, have also shown promise in repairing damaged neural circuits and promoting the recovery of normal sensory functions. These approaches represent a growing area of research that seeks to harness the regenerative potential of the nervous system to address the underlying causes of chronic pain.

The convergence of molecular insights and therapeutic advancements offers new hope for patients suffering from chronic pain. By elucidating the fine balance between adaptive and maladaptive plasticity, and by developing interventions that can tilt this balance towards recovery, there is potential for more effective, long-lasting treatments that can significantly improve patients' quality of life. The following sections will delve into the detailed mechanisms of pain-related plasticity and explore current and emerging therapeutic modalities aimed at targeting these complex processes.

Table 1: Key Differences Between Adaptive and Maladaptive Plasticity in Pain Processing

Feature	**Adaptive Plasticity**	**Maladaptive Plasticity**
Role in Pain	Facilitates recovery from acute pain by restoring neural function and maintaining homeostasis	Leads to chronic pain by amplifying and prolonging pain signals beyond the healing phase
Mechanisms	Axonal regeneration, synaptic strengthening, restoration of sensory pathways	Central sensitization, increased nociceptor excitability, reorganization of cortical areas
Outcome	Resolution of pain, return to baseline sensory function	Persistent pain, hyperalgesia, allodynia
Therapeutic Implications	Aims to promote healing and functional recovery	Focuses on reversing abnormal changes to reduce pain

Understanding the distinction between adaptive and maladaptive forms of plasticity is crucial for guiding therapeutic strategies. The ability to differentiate between changes that support recovery and those that drive chronic pain allows for a more tailored approach to treatment, minimizing the risk of long-term pain persistence. This knowledge has significant implications not only for pharmacological approaches but also for the design of neuromodulation devices and regenerative therapies aimed at repairing disrupted neural circuits. The next sections will further explore the mechanisms and pathways involved in these processes, providing a comprehensive understanding of the molecular underpinnings of pain-related plasticity and their potential as therapeutic targets.

2 Mechanisms of Neural Plasticity in Pain Processing

2.1 Peripheral Sensitization and Adaptive Changes in Nociceptors

Peripheral sensitization is a form of plasticity that occurs at the level of primary sensory neurons in response to tissue injury or inflammation. It involves a reduction in the activation threshold of nociceptors (pain-sensing neurons), leading to increased responsiveness to noxious stimuli. This process is mediated by the upregulation of ion channels such as TRPV1, Nav1.7, and Nav1.8, which contribute to enhanced action potential generation and transmission of pain signals. These

ion channels play crucial roles in regulating the excitability of nociceptors, with TRPV1 responding to heat and acidic conditions, while Nav channels contribute to the initiation and propagation of action potentials in response to tissue damage. The enhanced activity of these channels results in the increased frequency and duration of pain signals transmitted to the central nervous system, facilitating a heightened pain perception.

Adaptive changes in nociceptors can facilitate wound healing and protection of the injured area by temporarily increasing sensitivity to potentially harmful stimuli. This heightened sensitivity, also known as hyperalgesia, serves a protective role by encouraging the avoidance of further injury to the affected tissue. For example, neurotrophic factors like nerve growth factor (NGF) are released in response to injury, leading to the sensitization of nociceptors and promoting tissue repair. NGF increases the expression and function of TRPV1 and Nav channels on nociceptors, enhancing their sensitivity to thermal and mechanical stimuli. This adaptive response aids in the recovery process by ensuring that the injured area remains protected during the critical stages of healing. However, persistent upregulation of these pathways can result in maladaptive plasticity, characterized by ongoing pain even after the injury has healed, a hallmark of chronic pain conditions.

The transition from adaptive to maladaptive peripheral sensitization is influenced by sustained release of pro-inflammatory mediators such as prostaglandins, cytokines, and chemokines, which continue to activate nociceptors and maintain a state of heightened sensitivity. These mediators, released by immune cells and injured tissues, activate intracellular signaling pathways in nociceptors, leading to further upregulation of ion channels and prolongation of pain. For example, prostaglandins can enhance the activity of Nav channels, lowering the threshold for action potential initiation and contributing to ongoing pain signaling. Targeting these signaling molecules with anti-inflammatory drugs or ion channel blockers has been explored as a means to reverse maladaptive sensitization and reduce chronic pain. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen can inhibit cyclooxygenase enzymes, reducing the synthesis of prostaglandins and alleviating peripheral sensitization.

Table 2: Mechanisms and Mediators of Peripheral Sensitization in Pain

Mechanism	**Molecular Mediators**	**Outcome in Nociceptors**
Upregulation of Ion Channels	TRPV1, Nav1.7, Nav1.8	Increased action potential generation and heightened sensitivity to thermal and mechanical stimuli
Neurotrophic Factor Signaling	Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF)	Sensitization of nociceptors, promoting axonal growth and enhanced pain signal transmission
Pro-Inflammatory Mediators	Prostaglandins, cytokines (e.g., IL-6, TNF-α), chemokines	Prolonged activation of nociceptors, maintaining a state of hyperalgesia and chronic pain

2.2 Central Sensitization and Synaptic Plasticity in the Spinal Cord

Central sensitization is a key form of maladaptive plasticity that occurs in the dorsal horn of the spinal cord following nerve injury. It is characterized by an increased excitability of dorsal horn neurons, leading to the amplification of pain signals and the spread of pain sensitivity to adjacent areas (secondary hyperalgesia). This form of plasticity involves synaptic changes that persist even after the initial injury has resolved, resulting in the continuous perception of pain from otherwise non-painful stimuli, a condition known as allodynia. Central sensitization is driven by long-term potentiation (LTP)-like changes at synapses between primary afferent fibers and second-order neurons in the spinal cord.

Activation of NMDA receptors by glutamate is central to the induction of central sensitization. The excessive release of glutamate from primary afferent neurons leads to the prolonged activation of NMDA receptors on dorsal horn neurons. Calcium influx through NMDA receptors activates intracellular signaling pathways such as CaMKII (calcium/calmodulin-dependent protein kinase II), protein kinase C (PKC), and mitogen-activated protein kinases (MAPKs), which enhance the insertion of AMPA receptors into synapses and increase synaptic strength. This results in a sustained increase in excitatory postsynaptic potentials (EPSPs) and heightened pain responses. The LTP-like changes strengthen the synaptic connections within pain pathways, leading to a persistent increase in pain sensitivity.

Additionally, neurotrophic factors like BDNF released by activated microglia contribute to central sensitization by downregulating the expression of KCC2, a potassium-chloride cotransporter. The reduction in KCC2 levels leads to a shift in the chloride gradient, reducing the efficacy of inhibitory signaling through $GABA_A$ receptors. This disinhibition further enhances the excitability of spinal neurons, promoting the maintenance of central sensitization. The combined effects of enhanced excitatory transmission and impaired inhibitory control create a state of hyperexcitability in the spinal cord, sustaining chronic pain conditions.

2.3 Cortical Reorganization and Maladaptive Plasticity in Pain Perception

Chronic pain is also associated with changes in brain regions involved in pain processing, such as the somatosensory cortex, anterior cingulate cortex (ACC), and insula. These regions form a complex network that integrates sensory, affective, and cognitive aspects of pain. Neuroimaging studies have revealed that chronic pain can lead to reorganization of cortical representations of pain, where increased activity in pain-related brain regions is correlated with the persistence of pain symptoms. This reorganization is indicative of the brain's plasticity in adapting to prolonged nociceptive input, but it also underscores the potential for maladaptive changes that contribute to the chronicity of pain.

Maladaptive plasticity in the cortex can manifest as changes in synaptic connectivity, alterations in neurotransmitter release (e.g., glutamate and GABA), and the formation of new neural circuits that sustain pain perception. For example, increased glutamatergic signaling in the ACC has been implicated in the emotional and affective components of chronic pain, contributing to the heightened perception of pain and its associated emotional distress. The persistent activation of pain-related cortical areas can lead to the development of pain memory traces, where the neural circuits associated with pain become overly active even in the absence of peripheral stimuli. In parallel, decreased GABAergic inhibition can lead to the loss of balance between excitation and inhibition in cortical pain networks, further perpetuating pain perception.

Strategies to reverse maladaptive cortical plasticity include non-invasive brain stimulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), which aim to modulate cortical excitability and restore normal neural function. These approaches can help reduce pain by promoting adaptive plasticity in pain-processing regions of the brain, potentially re-establishing the balance between excitatory and inhibitory neurotransmission. For instance, TMS has been shown to modulate cortical activity in the motor cortex, which in turn can influence pain perception by altering the activity of interconnected brain regions involved in pain. Such interventions offer a promising avenue for the non-pharmacological treatment of chronic pain, particularly for patients who do not respond to traditional analgesics.

Central sensitization and cortical reorganization represent critical mechanisms in the transition from acute to chronic pain. Understanding these mechanisms provides insight into potential therapeutic targets that can modulate maladaptive plasticity and promote recovery. The interplay between peripheral and central processes underscores the complexity of pain as a biopsychosocial phenomenon, where molecular changes are intricately linked to the perception of pain and its psychological impact. Addressing these mechanisms through targeted interven-

Table 3: Key Mechanisms of Central Sensitization and Cortical Reorganization in Chronic Pain

Mechanism	Molecular Mediators	Impact on Pain Processing
Central Sensitization in the Spinal Cord	NMDA receptors, CaMKII, PKC, BDNF, KCC2	Enhanced synaptic strength and reduced inhibition, leading to heightened pain sensitivity
Cortical Reorganization	Glutamate, GABA, neuroplastic changes in ACC and insula	Formation of persistent pain circuits, altered perception and emotional response to pain
Non-Invasive Modulation	TMS, tDCS	Restoration of cortical excitability balance, reducing chronic pain symptoms

tions may hold the key to alleviating chronic pain conditions and improving patient outcomes.

3 Therapeutic Strategies Targeting Neural Plasticity

3.1 Pharmacological Modulation of Ion Channels and Receptors

Pharmacological agents that target ion channels and receptors involved in pain signaling represent a key strategy for modulating neural plasticity. By focusing on the molecular mediators of pain pathways, these drugs aim to either enhance adaptive plasticity or inhibit maladaptive changes. One of the most studied targets in this domain is the NMDA receptor, which plays a crucial role in the development of central sensitization. NMDA receptor antagonists, such as ketamine, can inhibit excessive excitatory transmission in the dorsal horn of the spinal cord by blocking NMDA receptor activity. Ketamine has been particularly useful in treating refractory pain conditions, such as complex regional pain syndrome (CRPS) and neuropathic pain. However, its application is limited by significant side effects, including dissociation and hallucinations, necessitating careful monitoring and controlled usage. Despite these limitations, NMDA receptor antagonism remains an important strategy for interrupting the process of central sensitization.

In parallel, selective blockers of sodium channels, specifically Nav1.7 and Nav1.8, offer promise for targeting peripheral sensitization. These channels are often upregulated in nociceptors during tissue injury or inflammation, contributing to heightened neuronal excitability. Nav1.7 and Nav1.8 are particularly implicated in certain inherited pain disorders, highlighting their critical role in pain transduction. Inhibition of these channels can reduce hyperexcitability and diminish the initiation of pain signals at their source. Unlike non-selective sodium channel blockers, selective Nav1.7 and Nav1.8 inhibitors have the potential for fewer systemic side effects, making them an attractive option for long-term management of chronic pain.

Another key aspect of pharmacological modulation involves targeting pro-inflammatory signaling pathways that perpetuate peripheral and central sensitization. Agents like TNF-α blockers (e.g., etanercept) and COX-2 inhibitors (e.g., celecoxib) can reduce the synthesis and release of pro-inflammatory mediators, thereby decreasing the sensitization of nociceptors and reducing central excitability. These drugs are effective in managing conditions like rheumatoid arthritis and inflammatory neuropathies, where inflammation plays a significant role in maintaining pain.

Restoring the balance between excitatory and inhibitory signaling is also crucial for reversing maladaptive plasticity. Enhancing GABAergic signaling through the use of GABA agonists, such as benzodiazepines or baclofen, can help restore inhibitory control over pain pathways. In addition, drugs that promote the activity of Kv7 potassium channels (e.g., retigabine) can stabilize the resting membrane potential of neurons, reducing their excitability. The augmentation of potassium currents through Kv7 channels can counteract the increased excitability seen in

central sensitization, contributing to the stabilization of pain transmission and providing symptomatic relief in chronic pain conditions.

Table 4: Pharmacological Agents Targeting Neural Plasticity in Pain Management

Agent	Target Mechanism	Clinical Applications
NMDA Receptor Antagonists (e.g., Ketamine)	Inhibition of central sensitization by blocking NMDA receptor activity	Refractory neuropathic pain, complex regional pain syndrome (CRPS)
Nav1.7/1.8 Channel Blockers	Reduction of peripheral sensitization by inhibiting sodium channel-mediated excitability	Inherited pain disorders, localized neuropathic pain
TNF-α Blockers (e.g., Etanercept)	Decrease in inflammatory signaling, reducing peripheral and central sensitization	Rheumatoid arthritis, inflammatory neuropathies
GABA Agonists (e.g., Baclofen)	Enhancement of inhibitory neurotransmission in pain pathways	Spasticity-related pain, central sensitization

3.2 Neuromodulation Techniques: Spinal Cord Stimulation and TMS

Neuromodulation techniques such as spinal cord stimulation (SCS) and transcranial magnetic stimulation (TMS) have shown promise in modulating neural plasticity and providing relief from chronic pain. These approaches work by directly influencing the electrical activity of pain pathways, offering an alternative to pharmacological treatments, particularly when medication is ineffective or associated with intolerable side effects. SCS involves the implantation of electrodes along the dorsal columns of the spinal cord, through which electrical impulses are delivered to modulate sensory processing. This stimulation can inhibit the transmission of pain signals to the brain and reduce central sensitization by altering the excitability of neurons in the dorsal horn. Recent advancements in SCS, including high-frequency stimulation and burst stimulation, have demonstrated improved efficacy in managing complex neuropathic pain conditions. These newer stimulation paradigms offer more effective pain relief with fewer paresthesias compared to traditional SCS, making them a valuable option for patients with chronic pain.

TMS, a non-invasive brain stimulation technique, can modulate the activity of pain-processing regions in the brain and promote adaptive plasticity. Repetitive TMS (rTMS) applied to the motor cortex or prefrontal cortex has been shown to reduce pain by altering the excitability of cortical networks and enhancing descending inhibitory control over pain pathways. The mechanism of action of TMS involves the induction of electric currents in the brain, which can increase or decrease the activity of specific neuronal populations depending on the stimulation parameters. rTMS has been effective in conditions such as fibromyalgia and chronic migraine, where it helps to normalize altered cortical activity associated with chronic pain states. The ability of TMS to non-invasively modulate cortical plasticity makes it a promising tool for addressing the complex neuroplastic changes seen in chronic pain syndromes.

3.3 Regenerative Approaches: Stem Cells and Gene Therapy

Regenerative therapies, including stem cell transplantation and gene therapy, offer potential for repairing damaged neural circuits and promoting adaptive plasticity in chronic pain conditions. These approaches focus on harnessing the intrinsic regenerative capacity of the nervous system to restore normal function in injured pathways. Mesenchymal stem cells (MSCs) have been investigated for their ability to secrete anti-inflammatory cytokines and neurotrophic factors, which can support neuronal survival and axonal regeneration. MSCs can be administered via various routes, including intravenous or intrathecal injection, where they can modulate the immune environment and promote the repair of injured tissues.

Preclinical studies have shown that MSCs can reduce pain behaviors and improve nerve function following injury, offering a promising avenue for treating neuropathic pain and degenerative conditions.

Gene therapy approaches involve the delivery of genetic material to cells to induce the production of therapeutic proteins. For example, the delivery of genes encoding neurotrophic factors like BDNF or GDNF (glial cell-derived neurotrophic factor) has been explored as a means to promote axonal growth and synaptic repair. These neurotrophic factors can support the survival of injured neurons, enhance synaptic plasticity, and stimulate the regeneration of sensory and motor fibers. By targeting specific genes that regulate the expression of pain-related proteins, gene therapy can potentially restore normal function in pain pathways and reduce chronic pain. Although gene therapy is still in the experimental stage for pain management, its ability to provide sustained therapeutic effects through a single administration makes it a compelling option for long-term treatment.

Table 5: Regenerative Approaches in the Modulation of Neural Plasticity

Therapy	**Mechanism of Action**	**Potential Applications**
Mesenchymal Stem Cells (MSCs)	Secretion of anti-inflammatory cytokines and neurotrophic factors, support for axonal regeneration	Neuropathic pain, spinal cord injury, degenerative nerve conditions
Gene Therapy (e.g., BDNF, GDNF)	Delivery of genes to enhance neurotrophic support and promote neuronal repair	Chronic pain syndromes, peripheral nerve injuries
Neurotrophic Factor Gene Delivery	Stimulation of axonal growth and synaptic plasticity through expression of therapeutic proteins	Recovery from nerve damage, modulation of chronic pain pathways

These therapeutic strategies—ranging from pharmacological modulation to advanced regenerative approaches—highlight the diverse means by which neural plasticity can be targeted to treat chronic pain. Each strategy addresses different aspects of the neuroplastic changes that contribute to pain, offering a multi-faceted approach to pain management. By combining pharmacological, neuromodulatory, and regenerative techniques, it is possible to develop more personalized and effective treatments that address the underlying causes of chronic pain rather than merely masking symptoms. The next section will discuss the potential challenges in implementing these therapies and the future directions for research in this evolving field.

4 Conclusion

Neural plasticity plays a dual role in pain processing, enabling both adaptive recovery and maladaptive changes that contribute to chronic pain. This capacity for plasticity allows the nervous system to respond dynamically to injury, adjusting sensory pathways and restoring function in cases of acute pain. However, when the changes in neural circuits become dysregulated, the same mechanisms that aid recovery can drive chronic pain, characterized by heightened sensitivity and persistent nociceptive signaling. Understanding the mechanisms of plasticity at the molecular and cellular levels is essential for developing targeted interventions that can promote beneficial neural adaptations while suppressing pathological changes. This understanding includes insights into the roles of ion channels, neurotransmitters, neurotrophic factors, and intracellular signaling pathways that mediate changes in neuronal excitability and synaptic strength.

Advances in pharmacological agents, neuromodulation techniques, and regenerative therapies offer new possibilities for modulating plasticity and achieving effective pain relief. Pharmacological strategies have focused on reducing excitatory signaling and inflammation while enhancing inhibitory control, aiming to mitigate the effects of maladaptive plasticity in both peripheral and central nervous systems. Neuromodulation techniques such as spinal cord stimulation (SCS)

and transcranial magnetic stimulation (TMS) have demonstrated efficacy in modifying pain pathways by directly influencing neural activity. These approaches hold particular promise for patients who are unresponsive to conventional pharmacological treatments, offering a non-invasive means to alter the excitability of pain-processing networks. Additionally, regenerative therapies, including stem cell transplantation and gene therapy, have shown potential to repair damaged tissues and restore normal function in pain pathways, providing a path toward more sustainable recovery.

By aligning therapeutic strategies with the underlying biology of pain, it may be possible to improve outcomes for individuals suffering from chronic pain and enhance their quality of life. The integration of molecular insights with clinical practices allows for a more personalized approach to pain management, where treatments can be tailored to the specific mechanisms driving a patient's pain. This personalized approach not only has the potential to reduce the burden of chronic pain but also to minimize the side effects associated with more generalized analgesic therapies. Continued research into the dynamic nature of neural plasticity holds promise for transforming the management of chronic pain conditions. As our understanding of the interplay between adaptive and maladaptive changes deepens, new avenues for therapeutic intervention may emerge, offering hope for those who suffer from long-term pain. The future of chronic pain treatment lies in the ability to precisely modulate neural circuits, facilitating recovery and restoring the balance between pain sensitivity and protection. (;)

References

[1] Anderson, J., and Roberts, D. Role of neurotrophins in synaptic plasticity and neurodegenerative diseases. *Journal of Neurochemistry 134*, 2 (2015), 275–289.

[2] Bell, A., and Lewis, R. The role of ion channels in epilepsy: Mechanisms and potential therapies. *Epilepsy Research 116* (2015), 95–107.

[3] Chen, W., Lan, T., Sun, Q., Zhang, Y., Shen, D., Hu, T., Liu, J., Chong, Y., Wang, P., Li, Q., et al. Whole genomic dna methylation profiling of cpg sites in promoter regions of dorsal root ganglion in diabetic neuropathic pain mice. *Journal of Molecular Neuroscience 71*, 12 (2021), 2558–2565.

[4] Chen, W., Wang, X., Sun, Q., Zhang, Y., Liu, J., Hu, T., Wu, W., Wei, C., Liu, M., Ding, Y., et al. The upregulation of nlrp3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (tet2) contributed to diabetic neuropathic pain in mice. *Journal of Neuroinflammation 19*, 1 (2022), 302.

[5] Chen, Z., Zhang, C., Song, X., Cui, X., Liu, J., Ford, N. C., He, S., Zhu, G., Dong, X., Hanani, M., et al. Bzatp activates satellite glial cells and increases the excitability of dorsal root ganglia neurons in vivo. *Cells 11*, 15 (2022), 2280.

[6] Clark, J., and White, E. *Cellular Pathways in Neurodegeneration: Molecular Insights*, 1st ed. Springer, Berlin, Germany, 2011.

[7] Clarkson, E., and Adams, G. Protein misfolding and aggregation in amyotrophic lateral sclerosis. *Neurotherapeutics 13*, 3 (2016), 624–632.

[8] Cui, X., Liu, J., Uniyal, A., Xu, Q., Zhang, C., Zhu, G., Yang, F., Sivanesan, E., Linderoth, B., Raja, S. N., et al. Enhancing spinal cord stimulation-induced pain inhibition by augmenting endogenous adenosine signalling after nerve injury in rats. *British journal of anaesthesia 132*, 4 (2024), 746–757.

[9] Ding, Y., Hu, L., Wang, X., Sun, Q., Hu, T., Liu, J., Shen, D., Zhang, Y., Chen, W., Wei, C., et al. The contribution of spinal dorsal horn astrocytes in neuropathic pain at the early stage of eae. *Neurobiology of Disease 175* (2022), 105914.

[10] Ford, O., and Harris, I. Inflammatory pathways in parkinson's disease: The role of microglia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry 60* (2015), 52–60.

[11] Harrison, S., and Davies, J. Microglia activation in the pathogenesis of multiple sclerosis. *Frontiers in Neurology 3* (2012), 43.

[12] Howard, P., and Cooper, A. Mechanisms of cellular stress in neurodegenerative diseases. *Cell Stress & Chaperones 21*, 5 (2016), 709–720.

[13] Knight, D., and Foster, M. *Cell Signaling in Neurological Disorders*, 2nd ed. Wiley, New York, NY, USA, 2014.

[14] Liu, J., Shen, D., Wei, C., Wu, W., Luo, Z., Hu, L., Xiao, Z., Hu, T., Sun, Q., Wang, X., et al. Inhibition of the lrrc8a channel promotes microglia/macrophage phagocytosis and improves outcomes after intracerebral hemorrhagic stroke. *Iscience 25*, 12 (2022).

[15] Mason, K., and Taylor, J. Therapeutic approaches targeting synaptic dysfunction in autism. In *Proceedings of the International Conference on Neuroscience* (Paris, France, 2013), pp. 89–96.

[16] Murphy, E., and Scott, H. The role of mitochondrial dynamics in parkinson's disease. *Molecular Neurobiology 49*, 3 (2014), 945–957.

[17] Peterson, L., and Moore, B. Neurovascular dysfunction in alzheimer's disease: A focus on blood-brain barrier integrity. *Journal of Cerebral Blood Flow & Metabolism 37*, 3 (2017), 754–768.

[18] Phillips, M., and Edwards, V. Neuroinflammation and tau pathology in alzheimer's disease. *Journal of Neuroinflammation 11* (2014), 102.

[19] Russell, T., and Gray, S. Autophagy dysregulation in huntington's disease: Mechanisms and interventions. *Nature Neuroscience 15*, 10 (2012), 1317–1325.

[20] Stewart, E., and Lee, J. Mechanisms of synaptic degeneration in alzheimer's and parkinson's diseases. *Journal of Molecular Neuroscience 50*, 2 (2013), 193–204.

[21] Sun, Q., Hu, T., Zhang, Y., Wang, X., Liu, J., Chen, W., Wei, C., Liu, D., Wu, W., Lan, T., et al. Irg1/itaconate increases il-10 release to alleviate mechanical and thermal hypersensitivity in mice after nerve injury. *Frontiers in Immunology 13* (2022), 1012442.

[22] Thompson, N., and Evans, W. Glutamate signaling and excitotoxicity in neurodegeneration. *Neurobiology of Disease 88* (2016), 1–9.

[23] Walker, R., and Hughes, T. Endoplasmic reticulum stress in neuronal injury and repair. *Journal of Cellular Neuroscience 42*, 1 (2010), 57–68.

[24] Wright, L., and Williams, S. Advances in understanding glial cell function in cns disorders. In *Annual Conference of the European Society for Neuroscience* (Madrid, Spain, 2011), pp. 45–52.

[25] Wu, Q., Cui, X., Guan, L. C., Zhang, C., Liu, J., Ford, N. C., He, S., Chen, X., Cao, X., Zang, L., et al. Chronic pain after spine surgery: Insights into pathogenesis, new treatment, and preventive therapy. *Journal of Orthopaedic Translation 42* (2023), 147–159.

[26] Young, R., and Morgan, C. Calcium dysregulation in als: Pathophysiology and therapeutic approaches. *Neuroscience 278* (2014), 1–12.

[27] Zhang, C., Hu, M.-W., Wang, X.-W., Cui, X., Liu, J., Huang, Q., Cao, X., Zhou, F.-Q., Qian, J., He, S.-Q., et al. scrna-sequencing reveals subtype-specific transcriptomic perturbations in drg neurons of pirtegfpf mice in neuropathic pain condition. *Elife 11* (2022), e76063.

Affiliation of Musliudeen Toheeb Akanbi :
University of Ibadan